Sign In
8 Apr 2020 16:34
8 April 2020
Ā
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Ā
PDMR Dealing
Ā
Oxford BioDynamics Plc (AIM: OBD) announces that it has today received notice that Vulpes Testudo Fund, which is controlled by Non-Executive Director, Stephen Diggle, has purchased 22,002 Ordinary Shares of 1 pence each ("shares") at a price of 52.5p per share.
Ā
Following this transaction, Vulpes Testudo Fund is interested inĀ 273,002 Ordinary Shares, representing 0.29% of the Company's current issued share capital. Through the holdings of Vulpes Life Sciences Fund and Vulpes Testudo Fund, Stephen DiggleĀ is interested in 12,083,672 shares, representing approximately 13.05% of the Company's current issued share capital.Ā
Ā
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
Ā
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Stephen Diggle | ||||
2 | Reason for the notification | |||||
a) | Position/statusĀ | Director/PDMR | ||||
b) | Initial notification/ AmendmentĀ | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Oxford BioDynamics PlcĀ | ||||
b) | LEI | 2138005Y1TK258O5U928 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification codeĀ | Ordinary Shares of 1 pence each Ā ISIN: GB00BD5H8572 | ||||
b) | Nature of the transaction | Acquisition of ordinary shares | ||||
c) | Price(s) and volume(s) | Ā
Ā Ā | ||||
d) | Aggregated information - Aggregated volume - Price Ā | Ā
Ā Ā | ||||
e) | Date of the transaction | 7 April 2020Ā | ||||
f) | Place of the transaction | Outside a trading venue | ||||
Ā
For further details please contact:
Ā
Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO Ā | +44 (0)1865 518910 |
Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield John More Ā | +44 (0)20 7408 4090 |
FTI Consulting Financial Public Relations Adviser Natalie Garland-Collins Ā | +44 (0)20 3727 1000 |
Ā
Notes for Editors
Ā
About Oxford BioDynamics Plc
Ā
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry.Ā
Ā
The Company's award-winning, proprietary technology platform,Ā EpiSwitchā¢, offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.Ā
Ā
In particular,Ā EpiSwitchā¢ offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product reāpositioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Ā
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards forĀ UKĀ businesses.
Ā
The Company is headquartered in theĀ UKĀ and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visitĀ www.oxfordbiodynamics.com.
Ā
Ā
Oxford Biodyn (OBD)
Follow the stocks
